Reversing Synapse Loss Starts Today

For those with neurodegenerative diseases 
this could be a game changer.

Reversing Synapse Loss Starts Today

For those with neurodegenerative diseases 
this could be a game changer.

SPINOGENIX is developing a new class of regenerative therapeutics to restore memory and motor functions lost in neurodegenerative and psychiatric diseases.

Recent News

Spinogenix Awarded $3 Million NIH
Grant to Support Continued
Development of SPG302

Our Approach is Unique for Diseases of the Central Nervous System

SPG302 is an innovative treatment focused on regenerating synapses to reverse declines in cognitive and motor function, which is different than the many other therapeutics that are being developed for neurodegenerative conditions, which mostly aim to slow the degenerative process.

Patent-protected compound

Spinogenix has designed SPG302, a compound that acts in an entirely new manner to help restore the brain connections (synapses) lost in neurodegenerative disorders including Amyotrophic Lateral Sclerosis, Alzheimer’s disease and many others.

Reverse of the synaptic degeneration process

Spinogenix has demonstrated SPG302 as an innovative treatment for regenerating synapses to reverse declines in cognitive and motor function, which is fundamentally different from other therapeutics that aim to slow degeneration.

Once-a-day
tablet

Spinogenix has developed SPG302 as a once-a-day tablet, which is significantly different from recently approved antibody therapies for Alzheimer’s disease that require IV infusion by a healthcare professional.

 

Phase 1: Australia

Human clinical studies for SPG302 ongoing

The 1st Synaptic Regenerative Therapy

SPG302 is the first synaptic regenerative therapy to be tested in ALS, and Spinogenix is aiming to make it the first such therapy in Alzheimer’s as well.

Spinogenix Uses A
Unique Approach

Multiple NIH and DOD grant awards supporting our unique treatment for Alzheimer’s and ALS patients. Our approach leverages a unique mechanism of action to trigger the formation of new synaptic connections, in effect regenerating synapses that have been lost. 

Regeneration vs. Slowing Disease

Most therapeutic approaches for Alzheimer’s aim to slow progression, leaving unaddressed the need to regenerate lost synapses. In animal models of Alzheimer’s, SPG302 reversed synaptic and cognitive deficits, even in the face of continued production of the hallmark biomarkers amyloid beta and phospho-tau.

 

To my knowledge, this is the first clinical trial in ALS focused on regenerating synapses with a small molecule. It has the potential to be used in combination with many other treatments approved and in development.

-Dr. Merit cudkowicz, director of the Sean m. healey &
amg center for als at massachusetts general hospital